ClinicalTrials.gg
CompletedNCT07476768PAINDYSUpdated Aug 21, 2026

PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study

An interventional study of Visit 1 at the center in Fibrous Dysplasia of Bone and McCune Albright Syndrome, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Primary conditionFibrous Dysplasia, PolyostoticRegistry: Fibrous Dysplasia of BoneReclassifiedWhy we changed it
Registry
Fibrous Dysplasia of Bone — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fibrous Dysplasia, Polyostotic
Why
  1. The study's listed conditions name Fibrous Dysplasia, Polyostotic, a narrower term within Fibrous Dysplasia of Bone.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Fibrous dysplasia of bone (FD) / McCune-Albright syndrome (MAS) is a rare congenital bone disorder affecting one or multiple bones, caused by a mosaic somatic mutation of the GNAS gene. In some cases, it may be associated with endocrine or cutaneous abnormalities. The spectrum of bone disease is broad, ranging from isolated monostotic fibrous dysplasia to complete skeletal involvement. Functional prognosis can be complex due to pain, bone deformities, and fracture risk. The disease may initially be identified through non-specific clinical signs such as pain. Indeed, bone pain has been reported in up to 81% of adults and 49% of children, mainly affecting the lower limbs and the spine, with highly variable pain intensity that does not always correlate with the extent of bone lesions. This pain may persist throughout life and impact patients' daily activities.

In the general population, it is well known that chronic musculoskeletal pain following events such as surgery or fractures can be associated with central sensitization, a neurophysiological phenomenon characterized by hyperreactivity of the central nervous system, along with impaired modulation of pain through descending inhibitory pathways, a normally protective mechanism that becomes reduced. The pathophysiology of bone pain in FD/MAS remains poorly studied and poorly understood. The presence of central sensitization, reduced pain modulation, and hypersensitivity to everyday stimuli are rarely described but suggested by the existence of chronic pain often lasting many years. The mixed characteristics of pain experienced (nociceptive, neuropathic, inflammatory, or nociplastic) are also poorly defined. To date, no study has explored pain in FD/MAS using a psychophysical approach in comparison with a control population.

Our hypothesis is that patients with FD/MAS exhibit central sensitization with reduced pain modulation. This exploratory pilot study aims to investigate, through psychophysical approaches, the pathophysiological mechanisms underlying pain in FD/MAS.

Read the detailed description

This exploratory pilot study aims to compare central pain sensitization in adults with FD/MAS to that observed in age- and sex-matched healthy volunteers. The primary objective is to assess differences in conditioned pain modulation (CPM), a measure of descending inhibitory pain control and central pain modulation capacity. Secondary objectives include characterization of pain intensity and phenotype, clinical description of FD/MAS manifestations, comparison of thermal and mechanical pain sensitivity thresholds, identification of pain mechanisms (nociceptive, neuropathic, inflammatory, or nociplastic), and comparison of quality of life, sleep quality, anxiety/depression levels, and pain catastrophizing between patients and healthy controls. Blood biomarkers related to bone metabolism will also be compared between groups.

Patients regularly followed in the Rheumatology Department will be informed about the study during routine clinical visits. Patients not requiring regular hospital follow-up may be contacted by their rheumatologist, who will present the study and provide written information. A reflection period of at least seven days will be respected before scheduling the study visit. Participation remains voluntary, and informed consent will be obtained prior to any study procedures.

Healthy volunteers will be preselected from the Clinical Investigation Center volunteer registry and contacted to assess interest in participation. Eligible volunteers will receive study information and will benefit from the same reflection period before inclusion procedures.

Both groups of participants will attend a single visit at the center. During this visit, the objectives and procedures of the study will be explained by the physician. After verification of eligibility criteria and once written informed consent has been obtained, the following assessments will be performed:

  • A medical examination and inclusion-related questionnaires (including medical history and clinical characteristics, comorbidities, medication treatments, the WPI and the Kosek nociplastic pain algorithm).
  • A blood sample to assess bone biological markers (Fibroblast Growth Factor 23 (FGF23) and C-terminal telopeptides of type I collagen (CTX)).
  • A pain assessment including the visual analog scale, the Brief Pain Inventory (BPI), DN4, the PainDetect questionnaire, psychophysical pain assessment (thermal pain thresholds for heat and cold, mechanical pain thresholds, Sudoscan), and evaluation of central sensitization using the conditioned pain modulation (CPM) test, as well as the Pain Catastrophizing Scale (PCS).
  • Quality-of-life-related questionnaires including the Pittsburgh Sleep Quality Index (PSQI), the SF-36 quality of life questionnaire, and the Hospital Anxiety and Depression Scale (HADS).
02

Conditions studied

  • Fibrous Dysplasia of Bone
  • McCune Albright Syndrome

Browse trials for

Keywords

  • Pain Modulation
  • Pain
  • Fibrous Dysplasia
  • Pain Caracterization
  • Central pain sensitization
03

In context

Fibrous Dysplasia, Polyostotic Reclassified

23 studies on the registry are indexed under Fibrous Dysplasia, Polyostotic; 5 are open to participants now.

This study's enrollment of 39 is above the median of 34 across 12 interventional studies indexed under Fibrous Dysplasia, Polyostotic.

Browse Fibrous Dysplasia, Polyostotic studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.

Compared within Fibrous Dysplasia, Polyostotic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrous Dysplasia of Bone. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients :
  • Male or female over 18 years of age with fibrous dysplasia/McCune-Albright syndrome diagnosed by a rheumatologist.
  • Mentally and legally able to provide to participate in the study.
  • Affiliated with a health insurance system.
  • For healthy volunteers :
  • Male or female over 18 years of age.
  • Matched to patients by age and sex.
  • Mentally and legally able to provide informed consent to participate in the study.
  • Affiliated with a health insurance system.

Exclusion criteria

Exclusion Criteria:

  • For patients :
  • Medical and/or surgical history considered by the investigator or delegated physician to be incompatible with study procedures (e.g., amputation or physical limitation preventing completion of pain assessment tests).
  • Recurrent pain at sites planned for stimulation during thermal and mechanical testing (forearms or palms).
  • Presence of anxiety and/or depression defined as Hospital Anxiety and Depression Scale (HADS) score >11.
  • Use of analgesic medication within the week preceding inclusion.
  • Use of complementary treatments for analgesic purposes (e.g., vitamins, herbal products, cannabinoids).
  • Individuals under legal protection (guardianship or trusteeship) or deprived of liberty.
  • Pregnant or breastfeeding women.
  • Refusal to participate.
  • For heathly volunteers :
  • Medical and/or surgical history considered by the investigator or delegated physician to be incompatible with study procedures (e.g., amputation or physical limitation preventing completion of pain assessment tests).
  • Presence of sleep disorders defined as Pittsburgh Sleep Quality Index (PSQI) score >5.
  • Presence of anxiety and/or depression defined as HADS score >11.
  • Use of analgesic medication within the week preceding inclusion.
  • Use of complementary treatments for analgesic purposes (e.g., vitamins, herbal products, cannabinoids).
  • Individuals under legal protection (guardianship or trusteeship) or deprived of liberty.
  • Pregnant or breastfeeding women.
  • Refusal to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    fibrous dysplasia

    Other: Visit 1 at the center

  • Active comparator
    healthy volunteer

    Healthy volunteer matched for age and sex

    Other: Visit 1 at the center

Interventions

  • OtherVisit 1 at the center

    Pain assessment and quality of life evaluation

06

What researchers measure

Primary outcomes

  1. Central sensitization tests, measurement of the Conditioned Pain Modulation (CPM) effect

    The patients are seated, the ATS thermode associated with the Pathway is applied to the dominant forearm. From the baseline value of 32°C, the Pathway delivers a "Pain 60 / Test stimulus" for 10 seconds, and the patient scores the pain on a visual numerical scale from 0 to 100. Then, the Pathway delivers a "Pain 60 / Test stimulus" for 30 seconds, and the patient scores the pain on the same scale. Fifteen minutes after the end of the two stimulations, the patient immersed the non-dominant arm for 60 seconds in a water bath at 46.5°C. Then a second identical sequence of 10 and 30 second stimulations was performed, with the scores recorded after each stimulation on the visual numerical scale from 0 to 100. The CPM effect is measured by taking the difference between the pain scores on the visual numerical scale before and after immersion.

    Time frame: Visit 1 / Day 1

Secondary outcomes

  1. Visual Analog Scale

    This scale allows the patient to rate the pain on a 100-mm horizontal line with a movable cursor. It ranges from 0 mm (0 cm), corresponding to "no pain," to 100 mm (10 cm), corresponding to "worst pain imaginable." Participants indicate, using the cursor, the point on the line that best represents their level of pain. The distance (in mm or cm) between 0 and the participant's mark determines the intensity of pain.

    Time frame: Visit 1 - Day 1

  2. The Brief Pain Inventory Questionnaire (BPI)

    This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you). The BPI also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.

    Time frame: Visit 1 - Day 1

  3. Measurement of the threshold of sensitivity and pain perception induced by a thermal stimulus (hot and cold) at the Pathway - Médoc®

    The measurements will be performed using an ATS thermode applied to the dominant arm of the patients. The Pathway-Medoc system associated with the thermode allows, from a base value of 32°C, to deliver adjustable temperature peaks (in the hot or in the cold and according to a regular slope of 1°C) and controlled by fast feedback, which allows to adapt to the different sensitivity thresholds of the C and A fibers. This device will be used to evaluate: the sensitivity threshold to heat, the sensitivity threshold to cold, the pain threshold to heat and the pain threshold to cold. The determination of each threshold will be established by an average of three measurements.

    Time frame: Visit 1 - Day 1

  4. Measurement of mechanical pain thresholds and mechanical temporal summation

    Mechanical pain thresholds and mechanical temporal summation will be assessed using standardized mechanical stimulation. Mechanical pain thresholds will be measured with calibrated PinPrick stimulators using a modified method of limits, with stimuli applied to the palm of the dominant hand (or non-dominant if necessary). Thresholds will be calculated as the geometric mean of ascending and descending series. Mechanical temporal summation will be assessed using a 180 g Von Frey filament applied to the forearm. Pain intensity after a single stimulus and after a train of 10 stimuli at 1 Hz will be rated on a 0-10 visual analog scale. The temporal summation ratio will be calculated as the ratio between repeated and single stimulus pain ratings. Matched healthy volunteers will be tested at the same sites as patients.

    Time frame: Visit 1 - Day 1

  5. Pain assessment using the Neuropathic Pain Questionnaire (DN4)

    Neuropathic Pain (DN4): This questionnaire estimates the probability of neuropathic pain in a patient, by means of four questions divided into ten items to be ticked. The practitioner or clinical research associate in charge of the study interviews or examines the patient and fills in the questionnaire himself. Each item is marked with a "yes" or "no" answer. Each "yes" is worth a score of 1, and each "no" is worth a score of 0. The sum of the scores gives the patient's score (out of 10); if the patient's score is equal to or greater than 4/10, the test is positive.

    Time frame: Visit 1 - Day 1

  6. PainDETECT questionnaire

    Neuropathic pain components will be assessed using the PainDETECT questionnaire. This self-administered questionnaire evaluates pain quality, temporal pattern, and radiation to estimate the likelihood of neuropathic pain. The total score allows classification of pain as unlikely, possible, or likely neuropathic

    Time frame: Visit 1 - Day 1

  7. Small fiber neuropathy assessment (Sudoscan®)

    Small fiber neuropathy will be assessed using Sudoscan® (Impeto Medical, Paris, France), a rapid, non-invasive, and reproducible method for evaluating sudomotor function. The test measures electrochemical skin conductance of the hands and feet, reflecting sweat gland function and small fiber nerve integrity. Participants will be seated comfortably with palms and soles placed on stainless steel electrodes. A low-voltage current (4 V) will be applied for 2 minutes and 40 seconds. Electrochemical skin conductance values (µS) will be recorded for hands and feet, with lower conductance (\<40 µS) indicating the presence of small fiber neuropathy and higher conductance (\>60 µS) indicating normal function. Measurements will be performed twice, 30 minutes apart.

    Time frame: Visit 1 - Day 1

  8. Dynamic mechanical allodynia

    Dynamic mechanical allodynia will be assessed using a soft brush gently moved back and forth over the non-dominant forearm while the participant is seated comfortably in a quiet room. Pain intensity perceived during brushing will be rated on a 0-100 numerical rating scale.

    Time frame: Visit 1 - Day 1

  9. Presence of inflammatory pain

    Inflammatory pain will be assessed by the investigator during clinical examination according to current clinical criteria. The evaluation will be based on the presence of clinical signs suggestive of inflammation, including warmth, redness, swelling, edema, induration, and pain. The outcome will be reported as the presence or absence of inflammatory pain (Yes/No).

    Time frame: Visit 1 - Day 1

  10. Nociplastic pain

    Signs of widespread pain will be assessed through clinical interview to calculate the Widespread Pain Index (WPI), commonly used in nociplastic pain conditions. In addition, the presence of nociplastic pain will be determined based on an integrative assessment combining results from pain testing and clinical evaluation.

    Time frame: Visit 1 - Day 1

  11. Clinical characteristics

    Clinical characteristics will be collected from the clinical examination and routine care investigations and will include a description of skeletal involvement and extra-skeletal manifestations.

    Time frame: Visit 1 - Day 1

  12. The Pittsburgh Sleep Quality Index (PSQI)

    he PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction. The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score. The higher the overall score, the greater the impairment in sleep quality. An overall score \>5 is an indicator of sleep disturbance.

    Time frame: Visit 1 - Day 1

  13. The Hospital Anxiety and Depression Scale (HAD)

    It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21). To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.

    Time frame: Visit 1 - Day 1

  14. The 36-Item Short Form Survey (SF-36)

    The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.

    Time frame: Visit 1 - Day 1

  15. Pain Catastrophizing Scale (PCS)

    The PCS is a validated 13-item self-report questionnaire assessing catastrophic thoughts and feelings related to pain, including rumination, magnification, and helplessness. Items are rated from 0 to 4, with higher total scores indicating greater pain catastrophizing.

    Time frame: Visit 1 - Day 1

  16. C-terminal telopeptides of collagen type 1 dosage

    Evaluation of the CTX evolution after one year, defined as the difference \[after - before\], relative to the basal value (µg/L). For this purpose, a blood sample will be taken using 5 mL dry tubes.

    Time frame: Visit 1 - Day 1

  17. Fibroblast Growth Factor 23 dosage

    The dosage of FGF23 (pg/mL) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 6 mL EDTA tube.

    Time frame: Visit 1 - Day 1

07

Study locations

1 site
  • CHU clermont-Ferrand
    Clermont-Ferrand, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Jun 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 17, 2026
StartActual
Apr 8, 2026
Primary completionActual
Jun 17, 2026
CompletionActual
Jun 17, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476768
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Apr 8, 2026
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Aug 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion